<DOC>
	<DOCNO>NCT00662519</DOCNO>
	<brief_summary>The primary purpose study find give 12 week course Neulasta ( Pegylated granulocyte colony stimulate factor ( GCSF ) ) people type 1 diabetes ( T1D ) safe . The secondary purpose research study determin give GCSF patient T1D change immune system preserve insulin production .</brief_summary>
	<brief_title>Neulasta Type 1 Diabetes</brief_title>
	<detailed_description>As participant study follow happen : Blood test , Mixed meal Tolerance Test ( MMT ) find much C-peptide produce , Human Leukocyte Antigen ( HLA ) test , Hemoglobin A1C ( HbA1c ) test overall blood sugar control , randomize either receive 12 week course Neulasta ( Pegylated granulocyte colony stimulate factor ( GCSF ) ) placebo ( medication ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Must &gt; 12 year old confirm diagnosis `` recent onset T1D '' define : T1D &lt; 6 month , Stimulated Cpeptide â‰¥ 0.2 pmol/ml Presence least one diabetesrelated autoantibody ( e.g. , GAD , IA2 , IAA , ICA ) Normal screen value CBC Willing comply intensive diabetes management No history allergy GCSF Females reproductive potential must willing avoid pregnancy negative pregnancy test Known hypersensitivity E.Coliderived proteins , pegfilgrastim , Filgrastim , component product Chronic use steroid immunosuppressive agent Active infection Inability maintain intensive diabetes management Pregnancy History malignancy Currently participate another type 1 diabetes treatment study . Use noninsulin pharmaceutical affect glycemic control</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>